Curenetics

What Curenetics does

Curenetics is a London-headquartered AI precision oncology company developing Cure-IO, a multimodal data analysis platform designed to predict patient response to immunotherapy. The platform integrates genomic, histopathological, and clinical data through proprietary machine learning and deep learning models, and is reported to have been validated on more than 5,000 cancer patients. Outputs are delivered as probability scores indicating the likelihood of treatment success, with score bands of 80–90% described as suggesting a high probability of response. The core technology operates across three routes: OnceraPLUS for direct-to-patient delivery, a clinician- and hospital-facing decision-support solution, and an enterprise channel serving pharmaceutical companies and clinical research organisations for patient stratification, biomarker discovery, and trial optimisation. Founded in 2018 by Dr Sola Adeleke, an NIHR Academic Clinical Fellow in Clinical Oncology at King's College London, Curenetics has operational offices in London, Toronto (MaRS Discovery District), and Villejuif/Paris.

The business model spans multiple revenue streams: platform licensing of Cure-IO to pharma, biotech, and CROs; project-based clinical trial support services including pre-screening, cohort optimisation, and evidence generation; white-label and embedded AI integrations for partner platforms; and direct-to-patient testing delivered through OnceraPLUS. Pricing is not publicly disclosed and operates on a quote-based, bespoke engagement basis. The company is currently at Proof of Concept stage, supported by data partnerships with NHS and UK Biobank, and has secured non-dilutive funding including a Greater London Authority grant and selection for the DTC Quantum incubator programme led by STFC and the UKRI National Quantum Computing Centre. Recent milestones include winning the Diagnostics & Monitoring Track at TechBio UK 2025 and selection for the Mayo Clinic Platform_Accelerate cohort in 2026.

Customer segmentation is horizontal, addressing pharmaceutical companies developing immuno-oncology drugs, CROs seeking to improve recruitment and trial design, clinicians and hospitals requiring AI decision support, biotech and techbio innovators seeking AI capability without internal build-out, and cancer patients considering immunotherapy. Marketing and distribution rely on a combination of industry events (notably TechBio UK and BIA showcases), LinkedIn presence, the company website, and earned media in healthcare and quantum-industry publications. The management team is led by Founder and CEO Dr Sola Adeleke, with Nicholas Kennedy as Head of Commercial (30 years in healthcare/medical devices including J&J and B&L) and Dr Olamide Agbomeji as Non-Executive Director, with a CFO position listed as forthcoming.

Name

Curenetics

Legal name

Curenetics Limited

Website

https://curenetics.io

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Curenetics is an AI precision oncology company developing the Cure-IO platform, which predicts cancer patient response to immunotherapy by integrating genomic, histopathological, and clinical data, serving pharmaceutical companies, CROs, clinicians, and patients across the UK, Canada, and France.

Ownership category

akta.pro rank

Product category

AI Precision Oncology Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Immunotherapy response prediction
• AI oncology platform
• Precision oncology
• Clinical trial optimization
• Multi-omic data analysis

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Platform Licensing: Licensing of Cure-IO platform to pharma, biotech, and clinical research organisations for use in drug development and clinical trials. Provides access to AI-driven patient stratification and predictive analytics capabilities.
2. Clinical Trial Support Services: Project-based collaborations supporting pharma and CROs with pre-screening for toxicity and response, cohort optimisation, operational efficiency improvements, and evidence generation for regulatory-facing narratives.
3. White-label/Embedded AI Integration: White-label or embedded AI integrations where Cure-IO technology is integrated into partner platforms or workflows, enabling access to AI capability without requiring internal build-out.
4. Direct-to-Patient Testing: Immunotherapy response prediction test delivered directly to patients through the OnceraPLUS platform, providing patient-centric predictive insight for treatment decisions.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Curenetics develops an AI-driven platform (Cure-IO) that predicts which cancer patients will respond to immunotherapy by analyzing multimodal genomic, histopathological, and clinical data. It delivers immunotherapy response prediction tests across direct-to-patient, clinician, and pharma/CRO channels for treatment decision support and clinical trial optimization.

Product overview

Curenetics offers a unified platform architecture centered on the Cure-io platform, which delivers immunotherapy response prediction as its core capability. The Cure-io platform operates through multiple routes to market: the OnceraPLUS sub-product enables direct patient engagement; a clinician and hospital-facing solution provides decision-support within real clinical settings; and a research-focused channel serves pharma and CRO partners for discovery and development. The platform aggregates and analyzes complex patient data including genomics, medical imaging, and clinical records from hospitals and laboratories to build advanced AI models integrating multiple biomarkers.

Differentiator

Problem solved

Functional benefit

Brands

• Cure-IO: AI-driven immunotherapy response prediction platform that integrates multi-omic, clinical, and tumour microenvironment data to deliver actionable insights supporting discovery through late-stage clinical development. Validated in over 5,000 cancer patients.
• OnceraPLUS

Products and services

• Cure-IO Platform A secure, continuously learning computational platform and operating system for immuno-oncology that integrates multi-omic, clinical, and tumour microenvironment data to deliver immunotherapy response predictions, patient stratification, biomarker discovery, and trial optimisation. Validated in over 5,000 cancer patients. Used by pharma, biotech, CROs, clinicians, and hospitals.
• OnceraPLUS Direct-to-patient platform delivering the immunotherapy response prediction test in a patient-centric, consent-driven environment, providing patients predictive insight relevant to their treatment journey.
• Immunotherapy Response Prediction Test AI-powered test that predicts which patients will respond to immunotherapy by analyzing genomic, histopathological, and clinical data, delivering percentage scores indicating likelihood of treatment success. Helps doctors and patients choose effective therapies and reduce ineffective treatments and side effects.
• Clinical Trial Support Services Project-based collaborations supporting pharma and CROs with pre-screening for toxicity and response, cohort optimisation, operational efficiency improvements, and evidence generation for regulatory-facing narratives.

Quantifiable outcome

• Validated in over 5,000 cancer patients
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• DTC Quantum (DeepTech Catalyst)coreStrategic or Co-development Partner · 14 April 2026Curenetics was selected for the DTC Quantum incubator programme, which provides £50,000–£100,000 in R&D funding, access to cutting-edge research facilities, technical expertise, and tailored business support. The programme is led by the Science and Technology Facilities Council in collaboration with the UKRI National Quantum Computing Centre at Harwell Science and Innovation Campus.
• Science and Technology Facilities Council (STFC)coreStrategic or Co-development Partner · 14 April 2026STFC leads the DTC Quantum incubator programme that Curenetics joined. The programme provides R&D funding, research facilities, technical expertise, and business support for quantum technology commercialisation in healthcare, computing, data analysis, and energy-efficient infrastructure.
• UKRI National Quantum Computing CentrecoreStrategic or Co-development Partner · 14 April 2026Collaborates with STFC to lead the DTC Quantum incubator programme providing funding and technical resources to support quantum technology development and commercialisation for real-world applications.
• NHSminorOthersNHS is listed as a partner of Curenetics, likely providing access to clinical data and healthcare system collaboration for AI model development and validation.
• UK BiobankminorOthersUK Biobank is listed as a partner providing access to extensive anonymised datasets including genomic, histopathological, and clinical data for AI model training.
• University of HertfordshireminorStrategic or Co-development PartnerListed as a partner on the Curenetics website, suggesting collaboration in research and academic areas related to oncology and AI.
• Queen Mary University of LondonminorStrategic or Co-development PartnerListed as a partner on the Curenetics website, indicating academic collaboration in cancer research and AI development.
• Pharmaceutical CompaniescoreStrategic or Co-development PartnerCurenetics partners with pharma companies to de-risk immuno-oncology development by improving patient selection, reducing toxicity-related trial attrition, and accelerating clinical decision-making through Cure-IO platform access.
• Clinical Research Organisations (CROs)coreStrategic or Co-development PartnerCure-io helps CROs deliver more predictable recruitment and stronger sponsor outcomes by reducing screen failures through advanced patient stratification, enabling site-agnostic decision support, and supporting biomarker-led and adaptive trial designs.
• Academic InstitutionsminorStrategic or Co-development PartnerCurenetics welcomes collaborations with academics who share the goal of improving cancer treatment decisions through response prediction and translational analytics.
• CliniciansminorStrategic or Co-development PartnerCurenetics seeks collaborations with clinicians who can provide high-quality clinical and biomarker data to validate and deploy Cure-IO in real world workflows.

Scale indicators6 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• SOPHiA GENETICS: SOPHiA GENETICS offers an AI-driven platform that analyses complex genomic and radiomic data for clinical decision support across oncology and rare disease. It is directly comparable in using multimodal AI for diagnostic and treatment-decision support sold to hospitals and pharma.
• Owkin: Owkin applies AI and federated learning to multi-omic and clinical data for oncology drug discovery and patient stratification. It is the closest direct peer given its pharma/CRO enterprise model, multimodal AI stack, and focus on immuno-oncology biomarkers.
• PathAI: PathAI applies deep learning to histopathology images for cancer diagnosis and biomarker discovery, partnered with pharma. It is comparable to the histopathology-image component of Curenetics' multimodal stack and shares a similar pharma-licensing GTM.

Broad incumbents

• Foundation Medicine (Roche): Foundation Medicine provides comprehensive genomic profiling assays used by oncologists to guide therapy selection, including for immunotherapy. It is a broad incumbent operating at much larger scale than Curenetics within the same immunotherapy decision-support category.
• Tempus AI: Tempus is a large precision medicine company combining multi-omic sequencing, AI, and clinical data for oncology decision support and pharma partnerships. It is a broad incumbent with overlapping capabilities (multi-omic AI, immunotherapy response) but a far larger dataset and footprint.

Emerging players

• Caris Life Sciences: Caris combines molecular profiling (DNA, RNA, protein) with AI to support therapy selection, including immunotherapy. It overlaps meaningfully with Cure-IO's molecular + AI stratification thesis while being more established in the US market.
• Ibex Medical Analytics: Ibex applies AI to pathology workflows for cancer detection and diagnosis, with deployments in hospital labs. It overlaps with the histopathology component of Cure-IO and shares a clinical-decision-support angle, though Ibex focuses on diagnosis rather than immunotherapy response prediction.
• Guardant Health: Guardant Health specialises in liquid biopsy and genomic profiling for oncology, including immunotherapy response biomarkers. It is comparable through its use of AI on molecular data to guide oncology treatment decisions, though its core modality (ctDNA) differs from Cure-IO's tissue-based multimodal approach.
• Paige: Paige uses AI on digital pathology slides to support cancer diagnosis and biomarker discovery, with pharma partnerships. It overlaps with the histopathology and biomarker-discovery slice of Curenetics' platform and pursues a similar enterprise licensing model.

Regional players

• Eden Bio: Eden Bio (UK) provides AI-driven drug discovery and biomarker analytics for biotech and pharma partners, including in immuno-oncology. It is a UK regional peer offering AI + multi-omic services to pharma, comparable in geography, stage, and target customers though with a broader discovery focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curenetics